Synpromics was founded in 2010 to commercialise technology developed by chief scientific officer Dr Michael Roberts in the “highly disruptive” field of synthetic biology – which gives researchers the ability to create man-made DNA sequences to aid the development of cures for conditions such as haemophilia and hereditary blindness.
Our move is the result of two incredibly successful years for the company...we’ve signed gene therapy deals with a large, orphan disease pharma company; and a US biotech specialising in gene editing and developing rare disease gene therapies.David Venables, Chief Executive, Synpromics
The firm is now lauding the next step in its growth and development with the move to the new site, after signing deals to provide gene therapy and bioprocessing with huge clients.
The ground-breaking developments allow for researchers to create gene “promoters” which are not naturally occurring with DNA – driving gene expression in any cell type – with each promoter representing a different invention that can be patented.
The Roslin Innovation Centre, adjacent to the University of Edinburgh’s Bush Campus, offers mixed-use space, and the company will occupy both office and lab space.